Swiss National Bank
RXRX icon

Swiss National Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Swiss National Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46M Buy
942,600
+65,600
+7% +$218K ﹤0.01% 1647
2026
Q1 		$2.69M Buy
877,000
+156,700
+22% +$606K ﹤0.01% 1700
2025
Q4 		$2.95M Buy
720,300
+99,700
+16% +$494K ﹤0.01% 1660
2025
Q3 		$3.03M Buy
620,600
+54,400
+10% +$286K ﹤0.01% 1630
2025
Q2 		$2.86M Buy
566,200
+82,900
+17% +$407K ﹤0.01% 1595
2025
Q1 		$2.56M Sell
483,300
-3,400
-0.7% -$24.8K ﹤0.01% 1617
2024
Q4 		$3.29M Buy
486,700
+129,600
+36% +$871K ﹤0.01% 1556
2024
Q3 		$2.35M Buy
357,100
+1,900
+0.5% +$13.6K ﹤0.01% 1776
2024
Q2 		$2.66M Buy
355,200
+46,700
+15% +$407K ﹤0.01% 1668
2024
Q1 		$3.08M Buy
308,500
+27,100
+10% +$302K ﹤0.01% 1598
2023
Q4 		$2.77M Sell
281,400
-2,700
-1% -$19.3K ﹤0.01% 1657
2023
Q3 		$2.17M Buy
284,100
+4,600
+2% +$45.9K ﹤0.01% 1790
2023
Q2 		$2.09M Buy
279,500
+161,900
+138% +$1.13M ﹤0.01% 1859
2023
Q1 		$784K Sell
117,600
-2,000
-2% -$15.9K ﹤0.01% 2377
2022
Q4 		$922K Buy
119,600
+3,100
+3% +$30.4K ﹤0.01% 2385
2022
Q3 		$1.24M Buy
116,500
+3,700
+3% +$37.5K ﹤0.01% 2211
2022
Q2 		$918K Buy
112,800
+18,500
+20% +$124K ﹤0.01% 2415
2022
Q1 		$675K Buy
94,300
+6,700
+8% +$71.2K ﹤0.01% 2533
2021
Q4 		$1.5M Buy
+87,600
New +$1.65M ﹤0.01% 2228

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Swiss National Bank's RXRX Position: Q2 2026 in Review

Swiss National Bank increased its Recursion Pharmaceuticals (RXRX) stake by 7.5% in Q2 2026, buying an estimated $218K and bringing the position to 942,600 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Swiss National Bank first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Swiss National Bank held 942,600 shares of Recursion Pharmaceuticals worth $3.46M as of Q2 2026.
  • Swiss National Bank bought 65,600 Recursion Pharmaceuticals shares in Q2 2026, an estimated $218K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1647 holding.
  • Swiss National Bank first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.